linjc16/ctgov huggingface dataset:
Physical Therapy Interventions Following Arthroscopic Rotator Cuff Repair

Study Overview
=================
Brief Summary
-----------------
In the post-arthroscopic rotator cuff repair (ARCR) management, physical therapy intervention is an important factor in bringing about a clinically positive prognosis. However, no conclusive therapeutic evidence has been found for various physical therapy interventions. In this study, the investigators would like to investigate the effects of physical therapy interventions on ARCR patients.

Official Title
-----------------
Physical Therapy Interventions Following Arthroscopic Rotator Cuff Repair: A Prospective Single Group Interventional Study

Conditions
-----------------
Rotator Cuff Injuries, Pain, Postoperative, Kinesiophobia

Intervention / Treatment
-----------------
* Behavioral: physical therapy intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults over 18 years old In case of 2 weeks after receiving arthroscopic rotator cuff repair When the participants wishes to enroll in the study Exclusion Criteria: 65 years old or older If the tear area is large and augmentation is performed If there is a previous surgical history at the surgical site Osteoarthritis in the shoulder joint

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: physical therapy intervention<br> | Behavioral: physical therapy intervention<br>* physical therapy interventions include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity | A numeric pain rating scale (NPRS) consisting of 11 points in total from 0 points (no pain) to 10 points (the most severe pain imaginable) is used. The lower the score, the less the pain. | Change from baseline pain intensity at 12 weeks |
Validation of the Quality of Recovery Questionnaire for the Postanesthesia Care Unit (QoR-PACU)

Study Overview
=================
Brief Summary
-----------------
Quality of recovery after surgery and anesthesia is an important endpoint in perioperative medicine. Several questionnaires have been developed that assess the patient's perception on postoperative recovery at 24 h after surgery. This study aims to adapt validate the Quality of Recovery 15-questionnaire for application in the postanesthesia care unit.

Official Title
-----------------
Adaptation and Validation of the Quality of Recovery 15-questionnaire for the Postanesthesia Care Unit

Conditions
-----------------
Postoperative Quality of Recovery in the Postanesthesia Care Unit

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective non-cardiac surgery general anesthesia fluency in German Exclusion Criteria: postoperative intensive care unit stay

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire|16-item quality of recovery questionnaire for the postanesthesia care unit (QoR-PACU)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 16-item quality of recovery questionnaire for the postanesthesia care unit (QoR-PACU) | Validity of the QoR-PACU | up to 4 hours following extubation |
Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.

Official Title
-----------------
Consolidative Prostate Radiotherapy in Patients With Metastatic Prostate Cancer

Conditions
-----------------
Prostate Metastases

Intervention / Treatment
-----------------
* Radiation: Radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically-proven metastatic prostate cancer Presence of low-volume or high-volume metastases (high volume defined as the presence of visceral metastases or ≥4 bone lesions with at least 1 lesion beyond the vertebral bodies and pelvis.) Planned to or receiving systemic treatment ADT +/- ARAT as per physician discretion (Previous chemotherapy allowed if completed more than 6 weeks prior to randomization.) Planned for EBRT ECOG 0 or 1 Age 18 years or older Exclusion Criteria: Prior radiotherapy to pelvis Active ulcerative colitis or Crohn's Disease, at discretion of treating physician Any condition where radiotherapy is contraindicated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1 - Investigational<br>Radiation treatment (36 Gy in 6 fractions) to be delivered every other day over 2 weeks (excluding weekends). | Radiation: Radiotherapy<br>* Standard of care radiotherapy administered as per institutional guidelines.<br>|
| Other: Arm 2 - Standard<br>Radiation treatment (36 Gy in 6 fractions) to be delivered once a week over 6 weeks. | Radiation: Radiotherapy<br>* Standard of care radiotherapy administered as per institutional guidelines.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rates of acute toxicity | Compare rates of acute toxicity between participants in Arm 1 and Arm 2. Acute toxicity will be measured using CTCAE V5.0 | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rates of late toxicity. | Compare rates of late toxicity between participants in Arm 1 and Arm 2. Acute toxicity will be measured using CTCAE V5.0 | 5 years | 
| Measure failure-free survival | Compare failure-free survival, collected through medical records, for participants in Arm 1 and Arm 2 | 5 years |
Evaluation of the Effect of Preoperative Symbiotic Bowel Conditioning on Surgical Site Infection After Elective Colorectal Surgery

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to investigate whether peri-operative symbiotic treatment could reduce the risk of postoperative infections in patients undergoing elective colorectal surgery. This study was also designed to assess the risk-adjusted incidence and predictors of surgical site infections.

Conditions
-----------------
Postoperative Wound Infection

Intervention / Treatment
-----------------
* Biological: Symbiotic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both genders More than 14 years old Candidate for elective colorectal surgery Exclusion Criteria: Denied written informed consent, Severe neutropenia, and Critically ill condition Not meeting inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Symbiotic<br>Symbiotic is a combination of prebiotics and probiotics that is designed to have synergistic or additive effects benefiting the host | Biological: Symbiotic<br>* Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of post-operative infection after elective colorectal surgery among patients with and without pre-operative symbiotic conditioning. |  | 15 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of postoperative infection including surgical site infections (SSIs) and distant-site infections after elective colorectal surgery in patients whether or not receiving pre-operative symbiotic conditioning. |  | 15 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Surgical site infection, Colorectal surgery, Symbiotic
Validation of Electrical Cardiometry Versus Fick Method in Cardiac Output Measurement

Study Overview
=================
Brief Summary
-----------------
The investigators would like to find out if AESCULON®, a new device that non-invasively and continuously measures cardiac output using electrical cardiometry, works as well as one existing method--Fick method in patients undergoing cardiopulmonary exercise testing.

Official Title
-----------------
Validation of Electrical Cardiometry Versus Fick Method to Measure Stroke Volume and Cardiac Output in Patients With or Suspected of Having Heart Failure

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >= 18 yd; Level 3 cardiopulmonary exercise testing. Exclusion Criteria: Proven or suspected disease involving severe aortic regurgitation; Implanted with a rate-responsive cardiac pacemaker; Pneumothorax or pleural effusion; Skin lesion(s) at the place where the electrode is supposed to be applied; Allergic to adhesive of ECG electrodes.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| difference in CO measurements with two methods | the true difference between the two CO measurements is 10% of the mean CO | two weeks after finishing the exercise test | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiopulmonary exercise test, cardiac output
Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)

Study Overview
=================
Brief Summary
-----------------
This is a Phase-II Study to evaluate the accuracy of Fluorodeoxyglucose-/Fluorothymidine-Positron Emission Tomography (FDG-/FLT-PET) analyses for early prediction of non-progression in patients with non-small-cell lung cancer (NSCLC) treated with Erlotinib.

Official Title
-----------------
A Phase-II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET for Early Prediction of Non-progression in Patients With Advanced NSCLC Treated With Erlotinib and to Associate PET Findings With Molecular Markers

Conditions
-----------------
Carcinoma, Non-Small-Cell Lung

Intervention / Treatment
-----------------
* Drug: erlotinib
* Procedure: FDG-/FLT-PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent ≥ 18 years of age Untreated non-small-cell lung cancer stage IIIB/IV Life expectancy > 3 months Performance status ECOG 0-2 Exclusion Criteria: Concurrent systemic immune therapy, chemotherapy or therapy with any anticancer drug not indicated in the study protocol Any investigational agent(s) within 4 weeks prior to study entry Previous administration of any EGFR-targeted therapy (antibodies, small molecules and others) Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: erlotinib<br>* erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)<br>Procedure: FDG-/FLT-PET<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the accuracy of FDG-/FLT-PET analyses for early prediction of non-progression in patients with NSCLC treated with Erlotinib |  | 34 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To identify PET characteristics for progression, response and stable disease; To identify EGFR and KRAS sequence characteristics for clinical response and stable disease; Safety; Response rates; One-year FFTF; One-year OS; Median overall survival time |  | 34 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
advanced Non-Small-Cell Lung Cancer, erlotinib, FDG-PET, FLT-PET
Prevalence of Two Major Geriatric Syndromes: Sarcopenia and Frailty

Study Overview
=================
Brief Summary
-----------------
Sarcopenia and frailty are two major syndromes in older adults. They are shown to be associated with low levels of functioning and higher rates of morbidity and mortality. In this study, we aim to report the prevalence of sarcopenia and frailty by using simple assessment methods such as SARC-F and FRAIL, respectively.

Official Title
-----------------
Prevalence of Two Major Geriatric Syndromes in Community- Dwelling Older Adults: Sarcopenia and Frailty

Conditions
-----------------
Sarcopenia, Frailty, Frailty Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being at the age of 65 or older Exclusion Criteria: <24 points on Mini-Mental State Examination 12 points or higher on Geriatric Depression Scale

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SARC-F | SARC-F is a rapid tool to assess sarcopenia in elderly. It is considered indicative sign of sarcopenia if the person scores 4 points or higher out of 10 points. | 5 minutes | 
| FRAIL | The FRAIL scale (Fatigue, Resistance, Ambulation, Illnesses, & Loss of Weight) is a simple questionnaire of frailty syndrome for older adults. If a patient scores 3-5 points over a total score of 5 points in the FRAIL, he is considered as frail. | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study of Osteoporotic Fracture (SOF) Criteria for Frailty | SOF is another index for measuring frailty. 2 or 3 points out of 3 points are considered as cut-off points for frailty. | 5 minutes | 
| Charlson Comorbidity Index | For comorbidity assessment | 5-10 minutes | 
| Rapid Assessment of Physical Activity (RAPA) | For the assessment of physical activity level | 10 minutes | 
| Mini-Nutritional Assessment (MNA) | Assessment of nutritional status | 10 minutes | 
| Katz Index of Independence in Activities of Daily Living | Assessment of activities of daily living | 10 minutes | 
| Lawton -Brody Instrumental Activities of Daily Living Scale | Instrumental activities of daily living assessment | 10 minutes | 
| Mini-Mental State Examination | Mini-Mental State Examination | 15 minutes | 
| Blood Sample Analysis | A blood sample analysis will be performed to investigate the relationship between blood parameters, sarcopenia and frailty. | 5 minutes | 
| Geriatric Depression Scale- Short Form | Assessment of depression | 10 minutes |
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient

Study Overview
=================
Brief Summary
-----------------
Paraneoplastic neurological syndromes (PNS) are rare complications of cancer occurring in 0.01% of cases. Their clinical, biological and radiological presentation is heterogeneous and may constitute a diagnostic challenge. Anti-Ma2 PNS are rare diseases with a guarded prognosis. They are most often associated with a seminoma-like testicular tumor but can also be associated with lung cancer. Classically, they present as limbic, diencephalic and/or brainstem encephalitis. Anti-Ma2 antibodies target intracellular receptors and are characteristic of a particular form of encephalitis. Atypical manifestations including narcolepsy-cataplexy, weight gain, sexual dysfunction and motor neuron syndrome have been described and explain the difficulty in diagnosing anti-Ma2 associated PNS. It seems interesting to better characterize the phenotypes of Ma2 patients in order to optimize the diagnosis and follow-up.

Official Title
-----------------
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient

Conditions
-----------------
Autoimmune Encephalitis, Paraneoplastic Syndromes

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnosis test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neurological disorder Anti-Ma2 positivity in sera or CSF Patient > 18 years old Exclusion Criteria: Patient without clinical data Patient without Ma2 antibody in sera or CSF

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient with Ma2 antibody<br>This is a non-interventional study involving biological samples. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids). | Diagnostic Test: Diagnosis test<br>* Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rankin score | Follow up and survival (rankin score) | 12 month after diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neurological paraneoplastic syndrome, auto immune encephalitis, Ma2 antibody
Supporting Trans Identities and Occupational Justice Through Narrative Informed Theatre: Supporting Trans Identities and Occupational Justice Through Narrative Informed Theatre

Study Overview
=================
Brief Summary
-----------------
Importance: Societal stigma gravely impedes occupational justice for trans individuals, producing vast health disparities for this population. Objective: Test feasibility and impact of an intervention to reduce stigma and improve trans wellbeing Design: Convergent parallel mixed methods Setting: Community/Webinar Participants: 42 audience members and 6 trans interviewees Intervention: Virtual, narrative-informed play reading and moderated discussion about gender diversity and affirmative care Outcomes and Measures: The valid and reliable Acceptance and Action Questionnaire - Stigma (AAQ-S) assesses stigma beliefs; An open-ended qualitative question assesses trans interviewees' experiences

Official Title
-----------------
Supporting Trans Identities and Occupational Justice Through Narrative Informed Theatre: A Mixed-methods Pilot Study

Conditions
-----------------
Transgenderism, Stigma, Social

Intervention / Treatment
-----------------
* Other: IDEAS (Identity Evolution and Sharing) Performance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18 or older Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Audience participants<br>Community members viewed the performance (intervention) and completed pre/post stigma questionnaire | Other: IDEAS (Identity Evolution and Sharing) Performance<br>* 60 minute webinar depicting first-hand stories of transgender and gender non-conforming individuals followed by expert panel/talk-back<br>* Other names: Performance;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acceptance and Action Questionnaire-stigma | The Acceptance and Action Questionnaire - Stigma (AAQ-S) survey | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gender, drama, disability studies, qualitative, stigma, affirmative care, minority health